- Conditions
- Biliary Atresia
- Interventions
- Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- Holterman, Ai-Xuan, M.D.
- Individual
- Eligibility
- 2 Weeks to 180 Days
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 694
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Social Isolation
- Interventions
- Project NOW
- Behavioral
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
- Interventions
- Campath Purged Non-myeloablative ASCT, Donor Apheresis
- Drug · Procedure
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Functional Deficits, Manipulation, Rehabilitation
- Interventions
- High Velocity Low Amplitude mobilization, Exercise Protocol
- Other
- Lead sponsor
- Shenandoah University
- Other
- Eligibility
- 16 Years to 35 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Winchester, Virginia
- Conditions
- Acute Leukemia, Myelodysplasia
- Interventions
- Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 28
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 22 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Donor, Lymphoblastic Lymphoma, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Thiotepa, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- bendamustine hydrochloride, dexamethasone, filgrastim, leukapheresis, laboratory biomarker analysis, flow cytometry, etoposide
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Orthopedic Disorder
- Interventions
- glenohumeral mobilization-oscillation, glenohumeral mobilization-sustained
- Other
- Lead sponsor
- University of New England
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Maine
- Conditions
- COVID-19
- Interventions
- Education, Motivational
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 778 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cervicogenic Headache
- Interventions
- Cervical-cranial dry needling, Orthopedic manual therapy, Thoracic Manipulation, Exercise, Patient Education
- Other
- Lead sponsor
- Youngstown State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Youngstown, Ohio
- Conditions
- Sickle Cell
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Social Support Mobilization, Individual Care Counseling
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Knee Osteoarthritis
- Interventions
- Manual Therapy, Therapeutic Exercise, Video Observation
- Procedure · Behavioral
- Lead sponsor
- Texas Tech University Health Sciences Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Lubbock, Texas
- Conditions
- Lymphoma
- Interventions
- Campath-1H, G-CSF, GM-CSF, BCNU, Stem Cell Transplant, Preparative Regimen for Allogenic Stem Cell Transplantation, Cytarabine, Etoposide, Melphalan, Campath, Fludarabine, Cyclophosphamide, Low dose total body irradiation
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
- Interventions
- GCSF, meloxicam, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Disease, Chronic Obstructive, Depression
- Interventions
- Problem Solving-Rx Adherence (PSA), PID-C
- Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- White Plains, New York
- Conditions
- Multiple Myeloma
- Interventions
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
- Drug · Behavioral · Biological
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Acute Stroke
- Interventions
- Acute Endovascular Stroke Treatment
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- New York, New York
- Conditions
- Uveal Melanoma
- Interventions
- IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
- Conditions
- Multiple Sclerosis
- Interventions
- Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
- Other
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Myeloma
- Interventions
- filgrastim, melphalan, Stem Cell Infusion
- Biological · Drug · Procedure
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Drug
- Lead sponsor
- Robert Nickel
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
- Conditions
- Scleroderma, Systemic, Sclerosis, Autoimmune Disease
- Interventions
- mHSCT, cyclophosphamide
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Lexington, Kentucky + 10 more
- Conditions
- Cardiac Rehabilitation
- Interventions
- Enhanced Physical Therapy Protocol
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas